Research/CAV vaccines
From Poultry Hub
Title: CAV vaccines
Project Leader: Glenn Browning at The University of Melbourne and Bioproperties funded by Poultry CRC (Project 03-08)
Duration of Project: Now completed (14 May 2004 to 30 September 2007)
Contents |
Project overview
Novel genetically modified strains of the significant avian pathogen Chicken Anaemia Virus (CAV) have been developed in previous RIRDC funded research. Further testing is needed to establish the value of these strains as vaccines and to identify the best candidate.
Project objectives
- Develop improved methods for assessing safety, efficacy and titre of CAV vaccine strains;
- Assess the suitability of attenuated mutants of CAV as commercial vaccines; and
- Determine the safety, stability, transmissibility and dose response relationships of potential vaccine strains.
Project progress
This project has been completed and the Final Report will soon be available from the Poultry CRC.
The optimal mutant of CAV for vaccine production was identified and a pre-master seedlot prepared. A method for production of the vaccine was assessed and the optimal time for preparation of vaccine material identified. Thymus tissue was shown to contain a thousand times more virus than liver or spleen. Molecular methods to support vaccine production were also developed.
See also
- Chicken anaemia virus infection (or CAV)
- Poultry CRC Project 03-09: Genomic approaches to novel vaccines
- Poultry CRC Project 03-16a: Genomics-based technology for new health products
- Poultry CRC Project 03-16c: Boosting innate immunity
- Poultry CRC Project 05-17: Transfer of diagnostic technologies to core diagnostic facility for the benefit of the Australian poultry industry
- Immune system
